Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.
Ther Adv Psychopharmacol August 1, 2014 DOI: 10.1177/2045125314527985 via PubMed Central
Summary
AI-generated from the abstractThis review examines the pharmacodynamics of classical hallucinogens and their potential clinical roles as antidepressants. It discusses how these compounds interact with serotonin receptors, particularly the 5-HT2A receptor, to produce their effects and explores the therapeutic promise they hold for treating depression. The authors synthesize evidence from preclinical and early clinical studies, noting that hallucinogens may promote neural plasticity and modulate mood-related circuits. They conclude that while preliminary findings are encouraging, more rigorous clinical trials are needed to establish safety and efficacy before these substances can be integrated into standard psychiatric practice.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Classical hallucinogens show potential as antidepressants through their action on serotonin receptors and promotion of neural plasticity, but further clinical research is required. |
Abstract
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.